The registration of clinical trials will help improve reliability
of data generated, help clinicians interpret research, minimize
duplication of trials and prevent exposure of volunteers to
potential risks.1 The Clinical Trial Registry India (CTRI; http://www.ctri.in/)
hosted at the National Institute of Medical Statistics (NIMS),
Indian Council of Medical Research (ICMR), New Delhi, was
formally launched on July 20, 2007. This is a free online registry
of clinical trials established with the aim to encourage all clinical
trials conducted in India to be prospectively registered before
the enrolment of the first participant and to disclose details
of the 20 mandatory items of the WHO International Clinical
Trials Registry Platform (ICTRP) dataset and a few additional
items.2 Thus, the CTRI becomes a WHO′s ICTRP and ICMJE
compliant Primary Register for India. Clinical trial has been
defined by the ICMJE.3Within about 3 months of its launch, the response received
has been overwhelming with over 90 clinical trials already
registered. But registration of trials is just a beginning. Active
steps are on to sensitize researchers who actually conduct trials,
funding agencies, ethics committee members, pharmaceutical
companies, health professionals and medical journal editors
on the need to register all trials that need registration. The
WHO′s ICTRP and ICMJE have drawn up clear guidelines on
these issues.4-6 However, only prospectively registered
clinical trials will be considered for publication.While participants of clinical trials volunteer with an altruistic
motive, it is too obvious that all is not well in experiments
involving human subjects.7 There have been reports that trials
have failed in their objective to carry out experiments fairly,
report honestly and follow the ethical principles in India
and abroad.8 There have been several instances of selective
reporting or not reporting at all, depending upon the outcome
of the trial and when financial interests are at stake. Despite
best efforts to ensure transparency and honesty, most initiatives
to discourage the conduct of unethical trials have largely been
unsuccessful.Attempts to regulate clinical trials through system of record
keeping at a public registry that would provide access to data
on trials being carried out have not been very successful,
as trial registration is voluntary and there is reluctance of
pharmaceutical companies to disclose data. As a step to ensure
complete awareness of trial details, the ICMJE proposed
comprehensive registration for clinical trials submitted for
publication for the 12 member journals [Annals of Internal
Medicine, British Medical Journal, Canadian Medical Association
Journal, Croatian Medical Journal, Journal of the American Medical
Association, The Dutch Medical Journal (Nederlands Tijdschrift voor
Geneeskunde ), New England Journal of Medicine, New Zealand
Medical Journal, The Lancet, The Medical Journal of Australia,
Tidsskrift for Den Norske Laegeforening, Journal of the Danish
Medical Association (Ugeskrift for Laeger)].3 Commencing July
2005, these journals have made registration of trials in a public
registry mandatory for consideration for publication. The
ICMJE did not indicate a particular registry, but any one that
meets a set of minimum criteria.With this background, the CTRI in association with
the Indian Journal of Medical Research (IJMR) organized a
meeting of editors of Indian biomedical journals to evolve
a policy to be followed for publication of clinical trials in
Indian biomedical journals. The meeting held at the ICMR
headquarters on October 9, 2007, was attended by 12 editors of
Indian biomedical journals. It was unanimously decided that
the editors have the responsibility to promote the registration
of all clinical trials being conducted in India and to urge
researchers to register their trials within a stipulated time, to
make the clinical trial data transparent and to enable results
to be published in good journals.On behalf of all biomedical journals published from India,
we urge to all those who are either conducting and/or planning
to conduct clinical trials involving human subjects, to register
their trials in CTRI or in any primary clinical trial register.
From January 2010 onwards, we will consider publication of
a trial only if it has been registered prospectively if started in
or after June 2008. Trials undertaken before June 2008 need to
be registered retrospectively.
Authors: Catherine D DeAngelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden Journal: JAMA Date: 2004-09-08 Impact factor: 56.272
Authors: Christine Laine; Richard Horton; Catherine D DeAngelis; Jeffrey M Drazen; Frank A Frizelle; Fiona Godlee; Charlotte Haug; Paul C Hébert; Sheldon Kotzin; Ana Marusic; Peush Sahni; Torben V Schroeder; Harold C Sox; Martin B Van der Weyden; Freek W A Verheugt Journal: CMAJ Date: 2007-06-04 Impact factor: 8.262